

The Manager
Company Announcements Office
ASX Limited

LBT INNOVATIONS PRESENTS RESULTS OF MOST EXTENSIVE STUDY OF LANDMARK APAS® TECHNOLOGY AT AUSTRALIAN CONFERENCE

Melbourne, 7 July 2014: Australian medical technology developer, LBT Innovations Limited (ASX: LBT), yesterday presented the results of its most extensive study to date into the efficacy of its Automated Plate Assessment System (APAS®) – a breakthrough culture plate analysis system based on the company's innovative intelligent image interpretation platform.

The presentation by LBT's Senior Microbiologist, at the Australian Society for Microbiology annual meeting in Melbourne, showed LBT's APAS® prototype matching the findings of two teams of experienced microbiologists – without missing a single potential pathogen.

The presentation was based upon the largest comparative study yet undertaken of the efficacy and accuracy of the automated APAS® system. Laboratory instruments that incorporate APAS are currently being developed in Europe in a joint venture with the Swiss instrumentation company, Hettich AG Switzerland.

Initial results of the APAS technology were unveiled at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona on 11 May. However, the results presented yesterday represent a far more wide-ranging and significant study group.

The APAS® system is a novel digital image analysis system that reads and interprets agar plates for the presence of infection-causing bacteria. As well as detecting colony growth, it can apply expert rule sets to enumerate various colony types and sort agar plates into categories for further processing. In this way, APAS can free microbiology technicians from the time-consuming work of sorting through agar plates – enabling them to spend more time identifying the right treatments for their patients.

LBT and Hettich's joint venture company, Clever Culture Systems AG, is currently in negotiations with potential global distribution partners/ The APAS® technology is due to undergo clinical trials in Australia and the US ahead of regulatory submissions later this year.

A copy of the Australian Society for Microbiology presentation can be downloaded from the LBT website at: <http://www.lbtinnovations.com/investor-centre/current-announcements/>

– ENDS –

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds.

LBT has an exclusive global licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories around the world. LBT's APAS® technology (the Automated Plate Assessment System) is nearing market. Based upon LBT's innovative intelligent image interpretation platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au